Cidara Therapeutics ( (CDTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cidara Therapeutics’ stock is on the rise following the expansion of its Phase 3 trial for CD388, which has doubled the potential U.S. target population from 50 million to over 100 million. This expansion has prompted analysts to raise their price targets, as the broadened study and accelerated timeline are viewed as strong future drivers. However, some concerns linger regarding the company’s financial performance and its reliance on external financing.
More about Cidara Therapeutics
YTD Price Performance: 210.48%
Average Trading Volume: 721,435
Technical Sentiment Signal: Buy
Current Market Cap: $2.25B
For further insights into CDTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.